5 results
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
Objectives: The following trial objectives for adolescent patients (from 12 and up to 18 years of age) with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:* Assess the effect of eculizumab on TMA-Event Free status…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
The main objective of this dose-finding study is to evaluate the analgesic effect of STR-324 (maximum 4 increasing doses and maximum 2-hours infusion) on post-operative pain, measured by change of pain intensity assessed on a Numerical Rating Scale…
The primary objective of the study will be to evaluate two low doses of a single intracoronary injection of rhIGF-1 compared with saline placebo on global LVEF by cardiac MRI and for safety (hypoglycaemia) in select subjects with STEMI and severe…